Tag Archive for: Poolbeg Pharma

Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases

/in

Clinical trial to demonstrate technology can safely deliver GLP-1 to commence in H1 2023 Prof Brendan Buckley joins Poolbeg’s Scientific Advisory Board to guide clinical development of technology Licence expands Poolbeg’s existing exclusive licence to AnaBio’s oral vaccine delivery technology Investor Meet Company presentation on 14 December 2022 at 5:30pm Read more…

Read more

Poolbeg Pharma plc. POLB 001 LPS human challenge clinical trial successfully completed. No serious adverse events reported. Results of full data analysis expected in Q2 2023

/in

12 December 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that, further to its announcement in July 2022, it has now received the initial results having completed the Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the […]

Read more